Stockreport

Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium

Zymeworks Inc.  (ZYME) 
Last zymeworks inc. earnings: 3/2 04:15 pm Check Earnings Report
US:NYSE Investor Relations: ir.zymeworks.com/overview
PDF Continued Clinical Benefit of Single Agent ZW25 in Heavily Pretreated HER2-High Patients VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymewo [Read more]